Ferric carboxymaltose,
does it really help with Improvement of fatigue, NYHA functional class, six-minute walk distance, and quality of life in chronic heart failure with reduced ejection fraction and iron deficiency?
research showsIntravenous ferric carboxymaltose is rated B when the claim is restricted to symptoms and function in chronic heart failure with reduced ejection fraction and iron deficiency. The 459-participant FAIR-HF and 304-participant CONFIRM-HF randomized trials improved symptoms, walking distance, and quality of life. The 3,065-participant HEART-FID trial, however, did not meet the prespecified 0.01 significance threshold for its primary hierarchical composite and showed six-month walk-distance changes of only 8 m versus 4 m, while the 1,105-participant FAIR-HF2 trial did not meet the Hochberg procedure for its three hard primary outcomes. Because large randomized results diverge, symptom and functional efficacy is separated from hospitalization and mortality efficacy and the rating is B with 66 points. Hypophosphatemia, infusion reactions, and hypersensitivity remain separate safety issues.
ads claimPromotion can broaden replenishing iron into improving heart-failure prognosis and survival. The demonstrated strength concerns fatigue, function, and quality of life in selected patients with laboratory-confirmed iron deficiency; it does not cover nonspecific fatigue, substitution for oral iron in every setting, or proven cardiovascular-mortality reduction.
Useful facts when choosing a product
- Ferric carboxymaltose is a prescription iron product administered intravenously in a medical setting; clinicians determine iron deficiency and total iron need from hemoglobin, ferritin, transferrin saturation, and clinical status.
- FAIR-HF and CONFIRM-HF enrolled symptomatic patients with laboratory-confirmed iron deficiency and reduced left ventricular ejection fraction, so their results do not apply to unexplained fatigue or heart failure without iron deficiency.
- Follow-up may include hemoglobin and iron indices as well as electrolytes such as phosphate, particularly because repeated high-dose exposure can cause symptomatic hypophosphatemia.
- Hypersensitivity, blood-pressure changes, nausea, and infusion-site reactions can occur during or soon after administration, requiring delivery in a setting equipped for observation and treatment.
What the research actually shows
FAIR-HF randomized 459 patients with iron deficiency, reduced left ventricular ejection fraction, and NYHA class II or III symptoms 2:1 to ferric carboxymaltose or saline. At 24 weeks, 50% versus 28% reported much or moderate improvement, 47% versus 30% were in NYHA class I or II, and six-minute walk and quality-of-life outcomes also favored treatment. CONFIRM-HF followed 304 participants for 52 weeks, finding a 33-m treatment effect on six-minute walk distance at week 24 and benefits in NYHA class, patient global assessment, fatigue, and quality of life. In contrast, HEART-FID randomized 3,065 participants and missed its prespecified 0.01 significance threshold for the primary hierarchical composite of death, heart-failure hospitalization, and walking-distance change (P=.02); six-month walk-distance changes were 8 m versus 4 m. FAIR-HF2 randomized 1,105 participants and found HR 0.79 for cardiovascular death or first heart-failure hospitalization (P=.04), RR 0.80 for total heart-failure hospitalizations (P=.12), and HR 0.79 for cardiovascular death or first hospitalization among those with baseline transferrin saturation below 20% (P=.07); none met the prespecified Hochberg multiplicity criteria.
Why this is classified as B (66)
FAIR-HF and CONFIRM-HF improved direct symptom and functional outcomes, including patient global assessment, NYHA class, fatigue, six-minute walk distance, and quality of life, which preserves B. The neutral HEART-FID hierarchical composite and small walk-distance contrast, failure of all three FAIR-HF2 primary outcomes under Hochberg criteria, and concentrated manufacturer support lower the result to B with 66 points. Hypophosphatemia and infusion or hypersensitivity reactions remain safety issues rather than deductions from efficacy.
Counterpoint. Ferric carboxymaltose can be considered as an adjunct to guideline-directed heart-failure therapy for symptomatic patients with confirmed iron deficiency. Persistent or recurrent fatigue still requires reassessment for anemia, bleeding, kidney disease, sleep disorders, and worsening heart failure.
Rejudgment record. Cross-check incorporated — Accepted direct symptom and functional benefits in FAIR-HF and CONFIRM-HF, while restricting the claim because HEART-FID in 3,065 participants had a neutral primary hierarchical composite and six-month walk-distance changes of 8 m versus 4 m, and FAIR-HF2 in 1,105 participants missed Hochberg criteria for all three hard primary outcomes
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Improvement in fatigue, patient global assessment, and NYHA functional class | B | Direct symptom outcomes were repeatedly positive in FAIR-HF and CONFIRM-HF, although manufacturer support is concentrated. |
| Improvement in six-minute walk distance and quality of life | B | Two randomized trials improved function and quality of life, with a 33-m treatment effect on six-minute walk distance at week 24 in CONFIRM-HF. |
| Reduction in heart-failure hospitalization and cardiovascular death | D | The HEART-FID primary hierarchical composite and all three prespecified FAIR-HF2 hard primary outcomes missed their significance criteria, so this efficacy is not established. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Anker SD et al.; FAIR-HF Trial Investigators. 2009 | Multicenter randomized double-blind placebo-controlled trial | 155 | Supported by Vifor Pharma, whose representatives participated in trial design and oversight | Patient global assessment and NYHA functional class at 24 weeks; six-minute walk and quality of life | Much or moderate improvement occurred in 50% versus 28%, NYHA class I or II in 47% versus 30%, and six-minute walk and quality of life also improved significantly. | Key direct symptom and functional randomized evidence |
| Ponikowski P et al. 2015 CONFIRM-HF | Multicenter randomized double-blind 52-week placebo-controlled trial | 304 | Supported by Vifor Pharma | Six-minute walk distance at 24 weeks; NYHA class, patient global assessment, fatigue, and quality of life | The placebo-adjusted treatment effect on six-minute walk distance was 33 m at week 24, with symptom, fatigue, and quality-of-life benefits observed through week 52. | Replicated direct functional randomized evidence |
| Mentz RJ et al.; HEART-FID Investigators. 2023 | Large multicenter randomized double-blind placebo-controlled clinical-outcome trial | 3,065 | Funded by American Regent, a Daiichi Sankyo Group company | Primary hierarchical composite of 12-month death, heart-failure hospitalization, and six-month change in six-minute walk distance | The primary hierarchical composite missed the prespecified 0.01 significance threshold (P=.02), and six-month walk-distance changes were 8 m versus 4 m. | Largest neutral trial establishing divergence in the randomized evidence |
| Anker SD et al. 2025 FAIR-HF2 DZHK05 | Multicenter randomized double-blind placebo-controlled hard-outcome trial | 1,105 | Supported by the German Center for Cardiovascular Research, German Heart Foundation, and CSL Vifor, which provided an unrestricted grant and study product | Cardiovascular death or first heart-failure hospitalization, total heart-failure hospitalizations, and cardiovascular death or first hospitalization in the subgroup with transferrin saturation below 20% | Results were HR 0.79 (P=.04), RR 0.80 (P=.12), and HR 0.79 (P=.07), but none of the three primary outcomes met the prespecified Hochberg significance procedure. | Key large randomized limitation on hard prognosis |
Receipt — 4 References
All 4 cited sources were verified for existence at the original page (as of 2026-07-21).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-21 · Corrections: none
Cite this verdict
[Chamgap] Ferric carboxymaltose x symptom and functional improvement in chronic heart failure with reduced ejection fraction and iron deficiency — Evidence Grade B·66. 4 cited sources checked. Source: https://chamgap.com/en/verdicts/energy/ferric-carboxymaltose-hfref-symptoms-functional-capacity/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.